Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin Duration Response in Glabellar Lines (COLD vs OLD)
NCT05305768Phase 1Unknown
- Sponsor
- Clinical Testing of Beverly Hills
- Start
- May 2022
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of botulinum toxin type A in glabellar rhytides (2 arms), sponsored by Clinical Testing of Beverly Hills. Primary endpoint: Response Duration at 180 days. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT05305768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305768.